First Time Use of SD-809 in Huntington Disease — First-HD

Chorea Clinical Trial

Official title:
A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety and tolerability of SD-809 for the treatment of chorea associated with Huntington's Disease. Approximately 90 subjects will be randomized (1:1) into the study, with approximately 45 subjects receiving SD-809 and 45 subjects receiving placebo. The study will be conducted at approximately 30 centers in the U.S. and Canada. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01795859
Study type	Interventional
Source	Teva Pharmaceutical Industries
Contact
Status	Completed
Phase	Phase 3
Start date	August 5, 2013
Completion date	December 5, 2014

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01019473` - Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea	Phase 2
Completed	`NCT00950196` - Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia	Phase 4
Completed	`NCT00368849` - Atomoxetine and Huntington's Disease	Phase 2
Completed	`NCT00271596` - Citalopram to Enhance Cognition in HD	Phase 2
Completed	`NCT04201834` - Risperidone for the Treatment of Huntington's Disease Involuntary Movements	Phase 2
Completed	`NCT00001930` - Treatment of Huntington's Chorea With Amantadine	Phase 2